Date: 2016-03-30
Type of information: Recruitment of the first patient
phase:
Announcement: recruitment of the first patient
Company: Oasmia Pharmaceutical (Sweden)
Product: Docecal® (docetaxel)
Action
mechanism: taxane derivative. Docecal is a nanoparticle and water soluble formulation of docetaxel in combination with the Company’s patented technology XR-17. Docetaxel is the most active substance in the cytostatic Taxotere®, marketed by Sanofi. Prior to the patent expiration in 2010, Sanofi-Aventis executed $3 billion in Taxotere® sales 2009. Taxotere® has continued to perform, generating sales of $350 million in 2014, clearly demonstrating market demand for the product. Taxotere® is used either as mono therapy or in combination with other anti-cancer medicine in the treatment of prostate cancer, breast cancer, lung cancer, gastric cancer and head & neck cancer. The product is a formulation of docetaxel and Polysorbate 80, a water soluble emulsifier made of polyethoxylated sorbitan and oleic acid. By comparison, Oasmia’s product Docecal® is solvent free and requires no pre-treatment.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On March 30, 2016, Oasmia Pharmaceutical announced that the first patient has been enrolled in the Phase I clinical study of the Company’s next-generation cancer treatment candidate Docecal®, to be performed internationally.
* On December 7, 2015, Oasmia Pharmaceutical announced that Docecal® has been approved for clinical clients and patient recruitment will commence in January 2016. Clinical trials with Docecal® are scheduled to begin in January 2016.
